TOKYO–(BUSINESS WIRE)–Mitate Zepto Technica (MZT, headquartered in Shibuya, Tokyo; CEO: Keisuke Harashima) announced today that its genome analysis-specific accelerator prototype, “RASEN,” has achieved precision equivalent to conventional methods. In a joint study with Tohoku University, RASEN demonstrated a 99.8% concordance rate compared to the widely used BWA tool, achieving a balance of speed and accuracy never before realized.
“The accuracy validation using the RASEN prototype demonstrates its capability to sufficiently achieve the design objective of accuracy equivalent to or better than BWA. This milestone highlights its potential for widespread use in genome analysis.”
Summary of Verification Results
High Concordance:
• Achieved an average concordance rate of 99.8% across all 12 samples.
• Several samples showed a perfect 100% match.
Consistent Precision:
• Maintained a concordance rate above 99.6% across all samples.
• No bias observed related to ethnicity or gender.
Reliable Mapping Accuracy:
• Discrepancies were minimal and consistent across samples.
• High reliability was confirmed through detailed visual inspections.
